Adverse Drug Reactions of Acetylcholinesterase Inhibitors in Older People Living with Dementia: A Comprehensive Literature Review
Sirasa Ruangritchankul,Prawat Chantharit,Sahaphume Srisuma,Leonard C Gray
DOI: https://doi.org/10.2147/TCRM.S323387
2021-09-04
Therapeutics and Clinical Risk Management
Abstract:Sirasa Ruangritchankul, 1 Prawat Chantharit, 2 Sahaphume Srisuma, 3 Leonard C Gray 4 1 Division of Geriatric Medicine, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 2 Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 3 Ramathibodi Poison Center and Division of Clinical Pharmacology and Toxicology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 4 Centre for Health Services Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia Correspondence: Sirasa Ruangritchankul Division of Geriatric Medicine, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Ratchathewi, Bangkok, 10400, Thailand Tel +66 816404373 Fax +66 22012588 Email The rising of global geriatric population has contributed to increased prevalence of dementia. Dementia is a neurodegenerative disease, which is characterized by progressive deterioration of cognitive functions, such as judgment, language, memory, attention and visuospatial ability. Dementia not only has profoundly devastating physical and psychological health outcomes, but it also poses a considerable healthcare expenditure and burdens. Acetylcholinesterase inhibitors (AChEIs), or so-called anti-dementia medications, have been developed to delay the progression of neurocognitive disorders and to decrease healthcare needs. AChEIs have been widely prescribed in clinical practice for the treatment of Alzheimer's disease, which account for 70% of dementia. The rising use of AChEIs results in increased adverse drug reactions (ADRs) such as cardiovascular and gastrointestinal adverse effects, resulting from overstimulation of peripheral cholinergic activity and muscarinic receptor activation. Changes in pharmacokinetics (PK), pharmacodynamics (PD) and pharmacogenetics (PGx), and occurrence of drug interactions are said to be major risk factors of ADRs of AChEIs in this population. To date, comprehensive reviews in ADRs of AChEIs have so far been scarcely studied. Therefore, we aimed to recapitulate and update the diverse aspects of AChEIs, including the mechanisms of action, characteristics and risk factors of ADRs, and preventive strategies of their ADRs. The collation of this knowledge is essential to facilitate efforts to reduce ADRs of AChEIs. Keywords: older adults, dementia, acetylcholinesterase inhibitors, adverse drug reactions, drug–drug interactions Globally, the number of older population aged 60 years or over was 962 million in 2017 and will almost double to reach 2.1 billion by 2050. 1,2 The rising geriatric population results in an exponential increase in incidence of neurodegenerative disorders such as dementia. 3,4 Worldwide, the population of people living with dementia was estimated at 50 million in 2017 and is predicted to increase to 131.5 million by 2050. 5,6 Dementia is described as symptoms related to a cluster of major neurocognitive disorders or conditions which are usually manifested as slowly progressive decline of multiple cortical functions including orientation, comprehension, memory, language, learning skills and problem-solving ability. 7 The most common type of dementia is AD (50–75%), followed by vascular dementia (20%), dementia with Lewy bodies (5%) and finally frontotemporal lobar dementia (5%). 8–10 In AD, the progressive loss of cholinergic neurons in the basal forebrain leads to a decrease in acetylcholine (ACh) which is essential in cognition and neuroprotection. 11 Dementia has a devastating impact on healthcare infrastructures in economic and medical aspects. This neurodegenerative disease is one of the leading causes of death and contributors to premature disability and dependency burdens. 5,12,13 With increased disability, dementia could be overwhelming for caregivers and families, leading to increased healthcare needs. 3,12,14–17 Appropriate management, including non-pharmacological and pharmacological therapies, are necessary to delay worsening of symptoms and to reduce healthcare burdens. 18 Anti-dementia medications are being used worldwide, especially in Alzheimer's disease (AD), which is the most common type of dementia. 19 One-fourth of older people with dementia are prescribed anti-dementia medications which are classified into two classes: Acetylcholinesterase inhibitors (AChEIs) and N-Methyl-D-aspartate (NMDA) receptor antagonists. 20,21 AChEIs were the first pharmacological treatment approved by the US Food and Drug Administration (FDA) for -Abstract Truncated-
health care sciences & services